Patients with a history of thyroid nodules, atypical moles, or family history of thyroid cancer require provider discussion before GLP-1 initiation
There is no upfront fee to complete your intake
Risks & Considerations While Retatrutide shows promise, experts caution about possible side effects: Bone fractures and kidney issues have been reported in some trial participants
CagriSema: Awaiting a Critical FDA Decision Novo Nordisks CagriSema represents one of the most consequential pending decisions across the GLP-1 drug pipeline in 2026
When food enters the digestive system, GLP-1 is released and acts on multiple targets: it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, slows gastric emptying, and promotes satiety through central nervous system pathways
If you miss a scheduled follow-up, your medication shipment can be held